Correlation between adult diabetic cataracts and red blood cell aldose reductase levels

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 5, 2006, Pages 2061-2064

  Oishi, Namiki ^a   Morikubo, Soichi ^a   Takamura, Yoshihiro ^a   Kubo, Eri ^a   Tsuzuki, Shosai ^a   Tanimoto, Tsuyoshi ^b   Akagi, Yoshio ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC CATARACT; DIABETIC PATIENT; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; BLOOD; ENZYMOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ALDEHYDE REDUCTASE; CATARACT; DIABETES COMPLICATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED;

EID: 33744775315     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1042     Document Type: Article

References (27)

1. Kinoshita JH. Cataracts in galactosemia. Invest Ophthalmol. 1965;4:786-799.
2. Kinoshita JH. Mechanisms initiating cataract formation. Invest Ophthalmol Vis Sci. 1974;13:713-724.
3. Datiles M, Fukui H, Kuwabara T, Kinoshita JH. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopy study. Invest Ophthalmol Vis Sci. 1982;22:174-179.
4. Hu TS, Datiles M, Kinoshita JH. Reversal of galactose cataract with sorbinil in rats. Invest Ophthalmol Vis Sci. 1983;24:640-644.
5. Kador PF, Inoue J, Secchi EF, et al. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats. Exp Eye Res. 1998;67:203-208.
6. Kador PF, Lee JW, Fijisawa S, Blessing K, Lou MF. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats. J Ocul Pharmacol Ther. 2000;16:149-160.
7. Banditelli S, Boldrini E, Vilardo PG, et al. A new approach against sugar cataract through aldose reductase inhibitors. Exp Eye Res. 1999;69:533-538.
8. Chylack LT, Wolf JK, Singer DM, et al. The Lens Opacities Classification System III. Arch Ophthalmol. 1993;111:831-836.
9. Tanimoto T, Maekawa K, Okada S, Nishimura-Yabe C. Clinical analysis of aldose reductase for differential diagnosis of the pathogenesis of diabetic complication. Anal Chim Acta. 1998;365:285-292.
10. Nishimura C, Hamada Y, Tachikawa T, et al. Enzyme immunoassay for erythrocyte aldose reductase. Clin Chem. 1994;40:889-894.
11. Leske MC, Wu SY, Hennis A, et al. Diabetes, hypertension, and central obesity as cataract risk factors in a black population. The Barbados Eye Study. Ophthalmology 1999;106:35-41.
12. Jahn CE, Janke M, Winowski H, Bergmann Kv, Leiss O, Hockwin O. Identification of metabolic risk factors for posterior subcapsular cataract. Ophthalmic Res. 1986;18:112-116.
13. Oishi N, Kubo E, Takamura Y, Maekawa K, Tanimoto T, Akagi Y. Correlation between erythrocyte aldose reductase level and human diabetic retinopathy. Br J Ophthalmol. 2002;86:1363-1366.
14. Klein BEK, Klein R, Lee KE. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: The Beaver Dam Eye Study. Am J Ophthalmol. 1998;126:782-790.
15. Skalka HW, Prchal JT. The effect of diabetes mellitus and diabetic therapy on cataract formation. Ophthalmology. 1981;88:117-124.
16. Burditt AF, Caird FI. Natural history of lens opacities in diabetes. Br J Ophthalmol. 1968;52:433-440.
17. Ederer F, Hiller R, Taylor HR. Senile lens changes and diabetes in two population studies. Am J Ophthalmol. 1981;91:381-395.
18. Leske MC, Chylack LT, Wu SY, Lens Opacities Case-Control Study Group. Risk factors for cataract. Arch Ophthalmol. 1991;109:244-251.
19. Bron AJ, Sparrow J, Brown NAP, Harding JJ, Blakytny R. The lens in diabetes. Eye. 1993;7:260-275.
20. Klein BEK, Klein R, Moss SE. Prevalence of cataracts in a population-based study of persons with diabetes mellitus. Ophthalmology. 1985;92:1191-1196.
21. Szmyd L, Schwartz B. Association of systemic hypertension and diabetes mellitus with cataract extraction. Ophthalmology. 1989;96:1248-1252.
22. Harding JJ, Egerton M, Heyningen Rv, Harding RS. Diabetes, glaucoma, sex, and cataract: analysis of combined data from two case control studies. Br J Ophthalmol. 1993;77:2-6.
23. Klein BEK, Klein R, Moss SE. Incidence of cataract surgery in the Wisconsin epidemiologic study of diabetic retinopathy. Am J Ophthalmol. 1995;119:295-300.
24. Datiles MB, Kador PF. Type 1 diabetes cataract. Arch Ophthalmol. 1999;117:284-285.
25. Akagi Y, Yajima Y, Kador PF, Kuwabara T, Kinoshita JH. Localization of aldose reductase in the human eye. Diabetes. 1984;33:562-566.
26. Akagi Y, Kador PF, Kinoshita JH. Immunohistochemical localization for aldose reductase in diabetic lenses. Invest Ophthalmol Vis Sci. 1987;28:163-167.
27. Chylack LT, Henriques HF, Cheng HM, Tung WH. Efficacy of alrestatin, an aldose reductase inhibitor, in human diabetic and nondiabetic lenses. Ophthalmology. 1979;86:1579-1585.